StockData
Viridian Therapeutics, Inc.\DE logo

Viridian Therapeutics, Inc.\DE (VRDN) company profile

VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30255% above fair value
$30.12+0.06 (+0.20%)

Close on Nov 18, 2026Market cap $3.41BP/E –Yield –

About Viridian Therapeutics, Inc.\DE

Pharmaceutical Preparations, SIC 2834

This biopharmaceutical company focuses on discovering, developing, and commercializing targeted therapies for serious autoimmune and rare conditions. Its research and clinical pipeline centers on therapeutic candidates addressing validated biological pathways, notably thyroid eye disease and related autoimmune indications. The company's core development programs feature anti-insulin-like growth factor 1 receptor product candidates, including the intravenous monoclonal antibody veligrotug and subcutaneous elegrobart. In addition, its pipeline includes neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008, alongside a thyroid-stimulating hormone receptor inhibitor program. Its end users are patients suffering from debilitating rare diseases, with commercial outreach targeting physicians and healthcare payors.

The business manages global clinical programs across international study locations, including trials throughout the United States. It maintains worldwide commercial rights for its leading product candidates, excluding Japan and greater China, where commercialization and development rights have been out-licensed to regional corporate partners. The provided excerpt does not state the company's headquarters location.

Summary of the business section of Viridian Therapeutics, Inc.\DE's latest annual report, written by StockData.

Company profile

Company

Legal name
Viridian Therapeutics, Inc.\DE
Headquarters
Waltham, MA
Address
221 Crescent Street, Suite 103a 02453
Phone
(617) 272-4600
Employees
252, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, Boston, Massachusetts

Stock & identifiers

Ticker
VRDN
Former tickers
MGEN until Jan 20, 2021; SGNL until Mar 24, 2017
Exchange
Nasdaq
IPO date
Jun 19, 2014
Shares outstanding
113M, Aug 3, 2026
Public float
$943.00M, Jun 30, 2025
Filer category
Large accelerated filer
Stock splits
1-for-15 reverse, Mar 26, 2021; 1-for-15 reverse, Nov 13, 2020; 1-for-15 reverse, Mar 24, 2017; 1-for-15 reverse, Nov 7, 2016; 1-for-13 reverse, Mar 27, 2015
SEC CIK
1590750
CUSIP
92790C104
ISIN
US92790C1045
FIGI
BBG002H242Z5
Share class FIGI
BBG002H24301
LEI
549300C775BNYF550E70
EIN
47-1187261

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Stephen F. MahoneyPresident and CEO, Director33,349
Jennifer TousignantChief Legal Officer0
Radhika TripuraneniChief Medical Officer40,000
Seth HarmonChief Financial Officer7,850
Thomas W. BeethamChief Operating Officer13,361
Jennifer K. MosesDirector–
Sarah GheuensDirector–
Jeffrey Robert AjerDirector–
Tomas KiselakDirector–
Arlene MorrisDirector–
Christopher W. CainDirector–
Funds Management LLC FairmountDirector3,459,913
Healthcare Fund II GP LLC FairmountDirector3,914,458
Healthcare Fund II L.P. FairmountDirector5,090,928

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$6.78M$18.85M$3.21M$189$125
FY2024$1.12M-$2.05M$2.05M$117$93
FY2023
Dr Violin
$2.21M-$744.99K$5.65M$132$94
FY2023
Mr Mahoney
$12.48M$22.38M$5.65M$132$94
FY2023
Mr Myers
$36.41M$6.25M$5.65M$132$94
FY2022$4.65M$7.62M$2.07M$178$90

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Stephen Mahoney
Chief Executive Officer
$700.00K–$1.06M$4.38M$630.00K$6.44K$6.78M+506%
Seth Harmon
Chief Financial Officer
$480.00K–$361.23K$1.50M$288.00K$17.65K$2.64M+243%
Jennifer Tousignant
Chief Legal Officer
$469.91K$50.00K$297.99K$1.23M$281.95K$18.09K$2.35M-52%
Thomas Beetham
Chief Operating Officer
$545.00K–$542.34K$2.25M$408.75K$19.23K$3.76M+365%
Radhika Tripuraneni$430.64K$50.00K–$3.34M$253.53K$4.89K$4.08M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 19, 2014
Offer price
$10.00
Securities offered
850,000
Gross proceeds
$8.50M
Exchange
Nasdaq
First trading day
Jun 18, 2014
First-day close
$9.09-9.1%
Lock-up ends (est.)
Dec 15, 2014

“Per Share Total Public offering price $ 10.00 $ 8,500,000 Underwriting discounts and commissions (1) $ 0.70 $ 595,000 Proceeds, before expenses, to us $ 9.30 $ 7,905,000 (1) The underwriters will receive compensation in addition to the underwriting discount.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we employed 252 full-time employees located in the U.S., including at our facilities in Waltham, Massachusetts and Boulder, Colorado.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jan 15, 2021Name changeName changed from MIRAGEN THERAPEUTICS, INC. to Viridian Therapeutics, Inc.DE
Oct 28, 2020Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 14, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 31, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 30, 2017Auditor changeChange in certifying accountant (8-K Item 4.01)
Feb 13, 2017Auditor changeChange in certifying accountant (8-K Item 4.01)
Feb 13, 2017Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Feb 10, 2017Name changeName changed from SIGNAL GENETICS, INC. to MIRAGEN THERAPEUTICS, INC.
Dec 2, 2016MergerRegistration of securities for a merger or exchange offer (S-4)
May 26, 2016Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 30, 2015Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 9, 2014Name changeName changed from SIGNAL GENETICS LLC to SIGNAL GENETICS, INC.
Jun 19, 2014IPOInitial public offering priced (424B4 prospectus)
Jun 6, 2014ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?